Creative Biolabs is a leading CRO company focusing on in vitro diagnostic (IVD) antibody development. With our extensive experience and advanced platforms, we provide a full package of IVD antibody development services against numerous markers for the diagnosis of multiple diseases. Here, we are happy to introduce our high-quality IVD antibody development services against cytokeratin 8 (CK8) marker for the diagnosis of bladder cancer.
CK8 is a member of the cytokeratins family which has 20 subgroups expressed and their type depends on the type of cell and location of CK in the cytoplasm. Based on its unique structural hallmark, CK8 provides structural support for cells. Studies have shown that CK8 has the widest range of expression in different types of epithelial and cancer cells among 20 types of CKs recognized so far. The expression of CK8 can be found on the surface of carcinoma cells in mammals but not in normal epithelial cells. Also, increased expression of CK8 has been reported in numerous diseases, such as colon, pancreatic, breast, and lung cancer.
Fig.1 Cytokeratin 8 staining in the human breast cancer cell line MCF-7.1
Bladder cancer (urothelial carcinoma) is the most common tumor of the urinary tract. It occurs more frequently among men about 65 years old on average. Until now, no specific diagnosis methods have been developed for the detection of bladder cancer. It has been reported that CK8 is presented at the external cell surface of tumor cells, while absent on healthy tissues. Biochemical approaches have demonstrated the capacity of cell surface-associated CK8 to bind a component of the urokinase plasminogen activator system, eventually leading to the activation of plasmin. Additionally, the urine level of CK8 in bladder cancer patients is significantly higher than that of healthy people. Under this condition, CK8 can be treated as a specific marker for the detection of bladder cancer.
Antibody-based immunoassays are critical tools for detecting and quantifying antigens of interest in all kinds of biological samples. Moreover, immunoassays have been extensively used in disease screening and therapeutic monitoring. To achieve superior sensitivity of immunoassays (or IVD kits), high-quality antibodies should be used for their development. As a leading IVD antibody development industry, Creative Biolabs now offers a full package of IVD antibody development services for global customers. With our versatile IVD platform, Creative Biolabs is proud to develop novel CK8-specific (paired) antibodies from scratch to commercial IVD kit (we can also start with provided antibody candidates).
In addition to CK8 marker, we also provide IVD antibody development services targeting other potential markers that you might be interested in. To learn more detailed information, please feel free to contact us or directly send us an inquiry.
Reference
For Research Use Only.
